trending Market Intelligence /marketintelligence/en/news-insights/trending/rgswtzOqPv51rLE7h7fy4A2 content esgSubNav
In This List

Vertex appoints chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Vertex appoints chief medical officer

Vertex Pharmaceuticals Inc. appointed Carmen Bozic as its chief medical officer.

Bozic has been with the company as senior vice president and head of global clinical development since May, leading the development of Vertex's cystic fibrosis and alpha-1 antitrypsin deficiency programs.

She will assume the new position April 1, 2020, replacing Reshma Kewalramani, who will become Vertex's president and CEO.

Bozic previously spent more than 20 years at Biogen Inc., where she led multiple functions, including global clinical development, safety, preclinical safety, regulatory, clinical operations and biometrics.